Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Enumeral Biomedical Holdings, Inc. ENUMQ

Healthcare Biotechnology
"Enumeral Biomedical Holdings Inc is a biopharmaceutical company engaged in the discovery and development of novel antibody immunotherapies that help the immune system fight cancer and other diseases. Its initial focus is on the development of a pipeline of next generation monoclonal antibody drugs targeting established and novel immuno-modulatory receptors."

Recent & Breaking News (OTCPK:ENUMQ)

Enumeral to Present at the Oppenheimer 26th Annual Healthcare Conference

Business Wire December 1, 2015

Enumeral Reports That Its Novel Class of Potentially Allosteric Anti-PD-1 Antibodies Can Elicit an Additive Effect on T Cell Activation in Ex Vivo Human Assays When Used in Combination with a Currently Marketed Anti-PD-1 Antibody

Business Wire November 18, 2015

Enumeral Reports Third Quarter 2015 Financial Results and Provides Corporate Update

Business Wire November 10, 2015

Enumeral Reports That Its Novel Class of Anti-PD-1 Antibodies Elicits Higher T Cell Activation in Ex Vivo Human Assays than Currently Marketed Anti-PD-1 Antibodies

Business Wire November 3, 2015

Enumeral to Present at the Emerging Concepts in Host Response to Cancer Symposium at The University of Texas MD Anderson Cancer Center

Business Wire October 5, 2015

Enumeral Announces Identification of Anti-PD-1 Antibodies with Potential for Differentiated Mechanism of Action

Business Wire September 24, 2015

Enumeral to Present at the CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference and BioPharm America 2015

Business Wire September 11, 2015

Enumeral Achieves First Milestone in Merck Collaboration

Business Wire September 8, 2015

Enumeral and UMass Medical School Enter Into Research Study Agreement

Business Wire August 26, 2015

Enumeral Reports Second Quarter 2015 Financial Results

Business Wire August 12, 2015

Enumeral Appoints Robert J. Easton to its Board of Directors

Business Wire July 30, 2015

Enumeral Announces Progress in PD-1, TIM-3 and Other Pipeline Programs

Business Wire July 14, 2015

Enumeral to Participate in Immuno-Oncology Panel at the Cantor Fitzgerald Inaugural Healthcare Conference

Business Wire July 1, 2015

Enumeral Expands Scientific Advisory Board to Support Development of Novel Immunomodulators

Business Wire June 4, 2015

Enumeral Reports First Quarter 2015 Financial Results

Business Wire May 15, 2015

Enumeral Reports Fourth Quarter and Year-End 2014 Financial Results

Business Wire March 19, 2015

Enumeral to Present Corporate and Program Overview at March Conferences

Business Wire March 17, 2015

Enumeral and the Ragon Institute of MGH, MIT and Harvard to Research Human Mucosal Immunology with Immune Profiling System

Business Wire March 9, 2015

Enumeral Appoints Paul J. Sekhri to its Board of Directors

Business Wire February 23, 2015

Enumeral to Present at Sachs Associates Cancer Bio Partnering & Investment Forum

Business Wire February 19, 2015